VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies Inc. has signed a patent license agreement with iPS Academia Japan, Inc. to license and commercialize iPS Academia Japan, Inc.’s patented technologies for induced pluripotent stem cell (iPS cell) research.
This agreement will enable STEMCELL Technologies to develop, manufacture, and distribute products that are optimized for cellular reprogramming. This further expands STEMCELL’s extensive portfolio of products for hPSC research, which includes ReproTeSR™ and TeSR™-E7™ media for reprogramming, the TeSR™ family of maintenance media, and the STEMdiff™ product line for robust and reliable differentiation to various cell lineages.
Help employers find you! Check out all the jobs and post your resume.
